From the Democratic Republic of Congo, to Cleveland, Through Hardship and Joy

August 8, 2016

On Thursday, July 21st, iForeignBorn went to an event at Lincoln-West High School where we met Mr. Crispin Kamucici, whose son was enrolled there. We learned that Crispin is a refugee from the Eastern part of the Democratic Republic of Congo who had lived in Kigali, the capital city of Rwanda, for 14 years before coming to the United States just a few months ago. His story sounded interesting to us, so we made a date to interview him the following week at “Egilse Evangelique Amour du Christ,” at the Metro Alliance Church building on Bridge Avenue, of which he is a minister.

Just as we expected, his story was both fascinating and inspirational. Mr. Kamucici told us how he lived with his wife, Nyota, and their seven children in the eastern part of the Democratic Republic of Congo where he served as a pastor and also did some accounting work.

A civil war broke out there so he fled with his family to Rwanda in 2002. They didn’t live in a refugee camp, however. Instead, they settled in Kigali where Mr. Kamucici found work as teacher of English and French as well as accounting. “These jobs helped me raise my children,” he said.

Along these lines, he and Nyota had several more children bringing the number to 10, who are now between the ages of 24 and 4 years old. He didn’t lose sight of his vocation of being a pastor, though, so in 2003 he founded the “Shekinah Apostolic Ministries Church” which had 100 members when he left to move to the United States to start a new life.

Accordingly, he and his family arrived in the United States on April 26, 2016. From what Mr. Kamucici told us, they have received good assistance from the Migration and Refugee Services (MRS) department of Catholic Charities Diocese of Cleveland. He really loves working with his case worker there who has done all that he can to make the family’s transition an easy one.

Ebola Virus Disease and Ebola Vaccines

Ebola virus disease (EVD) emerged at unprecedented epidemic levels in West Africa in 2014. Whereas previous EVD outbreaks were contained fairly quickly, this epidemic spread to crowded urban areas where transmissions continued unabated for many months.

Retrospective analysis indicates that the first case of the disease may have occurred at the end of 2013. An 18-month-old boy in a small village in Guinea became ill and died in late December, and the disease began to spread. It wasn’t until late March 2014 that the disease-causing agent was identified as Ebola virus. Through the fall of 2014, the epidemic was ongoing in Sierra Leone, Guinea, and Liberia. Nigeria and Senegal had small outbreaks related to importations from neighboring countries, but public health authorities there were able to contain spread of the disease. Several cases and deaths were reported from Mali, but spread was limited. In total, by the time the epidemic was over in March 2016, 11,325 confirmed, probable, and suspected deaths occurred. Total EVD cases numbered 28,652.

An ID card for voting? A “grocery ID card”? Donald Trump states in this clip “the time has come for voter ID”? Will this also mean mandatory vaccines that will be recorded on your ID card? The current “Ebola threat/outbreak” is being touted in the media as a “pandemic” when nothing could be further from the truth. Stories are being planted how Ebola is being transplanted to the US which will only effect how blacks think that without a vaccine they won’t survive Ebola. All these threats when most Americans don’t have a clue what is going on in west Africa.

President Trump Said ‘You Need An ID To Buy Groceries’ | TIME

Is this a public relations stunt to ramp up the ebola vaccine market? 81.34 million people in the Congo and only 3,300 Congolese received an “investigational dose” with a market expected to be worth $56 million in 2020?

The Ebola Vaccine market research offers a skillful and extensive analysis on the current state of the regional and international, targeting on the Ebola Vaccine capability and manufacture measures, producers, prices, import & export, market forecast and Ebola Vaccine consumers, including the unbiased historical data and long-term forecasts. This Ebola Vaccine report dispenses thorough inspection of international markets for Ebola Vaccine Market research report 2018 and delivers substantial Ebola Vaccine market predictions 2018-2027 by region/country and sub-sectors. It supplies in-depth comprehension of depletion by individual Ebola Vaccine product categories to orient your sales and marketing efforts with the latest trends in the Ebola Vaccine market. The report also calculates the Ebola Vaccine market size, the report contemplates the earnings produced from the sales of Ebola Vaccine report and technologies by different application sectors.

“Developed economies are interested in formulating therapeutics that can significantly minimize threats from Ebola virus. Companies operating in this market are currently focusing on clinical trials as a key strategy. The commercialization of Ebola therapeutics is the prime focus of healthcare systems, as there are no specific medications available in the market. Companies profiled in the report are Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics Corp and Mapp Biopharmaceutical.”

by Onkar Sumant

The new report by Allied Market Research titled, “Potential Analysis of Ebola drug and Vaccines Market – Global Opportunity Analysis and Industry Forecast to 2020” anticipates that the Ebola Virus Disease (EVD) vaccines would gain a market value of $56 million by 2020. The rampant growth of the disease in the under developed economics and increasing awareness among people about life threatening EVD disease has motivated healthcare authorities to introduce novel therapeutics.

Ebola, an orphan disease, has affected more than 20,000 people in the African countries as of now. Recurring outbreaks of Ebola in under developed region and lack of effective therapies are factors that drive the need for Ebola drugs and vaccines. The perennial outbreak of Ebola has given rise to a renewed interest among healthcare authorities in finding effective therapies. To control the EVD, the government authorities are supplying funds to pharmaceutical companies for research and development of EVD drugs and vaccines. As an example, the government of the United States, through the FDA, has granted Fast Track designation to the Tekmiras TKM Ebola drug and has funded $140 million through the Department of Defense, United States, for R&D on EVD. According to AMR analyst, Roshan Deshmukh, The prime focus of the companies is to commercialize the drugs and vaccines for EVD disease. The government authorities across the developed regions are extending support for the commercialization of these drugs by providing funds and floating favorable policies.

Is the real reason behind this current “Ebola outbreak” designed to ultimately get US soldiers inside Congo to control Congo’s natural resources competing against China and Russia for these resources? It would seem the only ones who got sick were the people who were given shots by the Red Cross. Why else would the Liberians and Nigerians have begun kicking the Red Cross out (cheap slave labor) of their countries? If this current threat of Ebola is a “pandemic” as being labeled, why are flights still continued to arrive and leave Congo regularly with apparently no regulation?

The following report suggests Ebola is a military operation and that the criminal banking elite are involved in this Ebola operation. Not only in creating the “Ebola outbreak” which explains why pharmaceutical companies are lining up to profit off any future Ebola vaccines outlined in the material published above, but USAID’s involvement. The USAID are in actuality “paramilitary social workers”. USAID are also set up in Congo with offices in Kinshasa and Gombe, Congo. They were the ones delivering globalization on the ground in the Congo so they knew probably better than anybody, the one-world, one-size fits all plan for globalization using the threat of Ebola with Ebola vaccine solutions.